AFRM stock · ZYME stock

AFRM vs ZYME · P/E 590, rev $3.22B vs rev $76.3M

Affirm Holdings Inc (AFRM) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.

Affirm Holdings Inc (AFRM) is a software - infrastructure company listed on US.

Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.

Latest reported AFRM revenue for 2025-06-30 was $3.22B. Net income was $52.2M. Revenue was up 38.8% from 2024-06-30 to 2025-06-30. AFRM currently screens at market cap $28.80B and trailing P/E 589.7.

Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.

AFRM currently screens at market cap $28.80B and trailing P/E 589.7. ZYME currently screens at market cap $1.68B.

Not investment advice. Open the AFRM and ZYME stock pages for the full models.

Not investment advice.

Popular Stock Comparisons